Matt Pauls, J.D., M.B.A.

Mr. Pauls has served as Chair of the Board of Directors and Chief Executive Officer of Savara since 2020. He also currently serves on the Board of Directors of Pelthos Therapeutics, a publicly traded biopharmaceutical company focused on dermatologic infectious diseases and the Board of Atsena Therapeutics, a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that cause blindness. From 2020 to 2026, Mr. Pauls served on the Board of Amplo Biotechnology, a private gene therapy company focused on rare neuromuscular disorders. From 2023 to 2026, he served on the Board of Directors of Soleno Therapeutics, a publicly traded rare disease biopharmaceutical company, where he was appointed Lead Independent Director in August 2024. Soleno was acquired by Neurocrine Biosciences in May 2026. From 2014 to 2019, Mr. Pauls was President and Chief Executive Officer and a member of the Board of Directors of Strongbridge Biopharma plc., a publicly traded rare disease focused biopharmaceutical company that he took public via IPO on the NASDAQ. Prior to 2014, he served as Chief Commercial Officer of Insmed, Inc., where he led both the global Commercial and Technical Operations organizations. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations, and earlier in his career held senior commercial leadership positions at Bristol Myers Squibb and Johnson & Johnson. In addition to his other Board positions, Mr. Pauls has also served as Chair of the Board of Directors of Mast Therapeutics and was a member of the Board of Directors of Zyla Life Sciences, both publicly traded biopharma companies. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.